AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15948916
Drug: Clinical drug
RxNorm normalized name: Product containing precisely paracetamol 1 gram/1 each prolonged-release oral tablet (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical drug trial
Trial: 2814916
Drug: Cyclosporine administered
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine administered orally twice a day (9 a.m. and 21 p.m.)
Trial: 791234
Drug: Promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 25 mg plus Ephedrine 12.5 mg
Trial: 791234
Drug: Promethazine 12.5
RxNorm normalized name: promethazine 12.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 12.5 mg plus Ephedrine 25 mg
Trial: 29266524
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive rehabilitation therapy program (eReCog)
Trial: 21796707
Drug: Curcumin 500
RxNorm normalized name: curcumin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 500 mg/day
Trial: 21796707
Drug: Curcumin 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 6 g/day
Trial: 16431893
Drug: ARB (Angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (Angiotensin II-receptor blockers)
Trial: 16431893
Drug: CCB (Calcium-channel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB (Calcium-channel blocker)
Trial: 12908681
Drug: Propofol (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.0 mg x kg(‐1) i.v.)
Trial: 10884325
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor subtypes immunohistochemically analyzed with subunit‐specific antibodies (alpha1, alpha2, alpha3, beta2,3, and gamma2)
Trial: 10884325
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor subunit staining
Trial: 10884325
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor alpha2‐subunit
Trial: 10884325
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor alpha1‐subunit
Trial: 10884325
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor beta2,3- and gamma2-subunits
Trial: 17926625
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (control)
Trial: 24016491
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing (using clinical information plus genotype)
Trial: 24016491
Drug: Clinical-guided dosing
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical-guided dosing (using only clinical information)
Trial: 21397626
Drug: Citicoline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline treatment for 8 weeks
Trial: 18313446
Drug: Ultralow-dose transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow-dose transdermal estradiol (0.014 mg/day)
Trial: 16983107
Drug: Simultaneous chemoradiotherapy
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous chemoradiotherapy (paclitaxel 60 mg/m2 weekly)
Trial: 16331853
Drug: Hospital-based medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based medical day-treatment program
Trial: 16331853
Drug: Community-based nonmedical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based nonmedical day treatment programs
Trial: 11386894
Drug: Warfarin in
RxNorm normalized name: warfarin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin in clinical practice
Trial: 9041624
Drug: Cefixime (CFX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (CFX; 8 mg/kg once daily)
Trial: 9041624
Drug: Amoxicillin/clavulanate (A/C;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (A/C; 40 mg/kg/day in three divided doses)
Trial: 9041624
Drug: Amoxicillin/clavulanate (A/C)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (A/C)
Trial: 28668857
Drug: Reiki treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reiki treatment
Trial: 29701561
Drug: G‐CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (300 μg/day, 7 subcutaneous administrations over 1 week)
Trial: 28087128
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (8 days/40 IU twice daily)
Trial: 28087128
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 days/10 puffs twice daily)
Trial: 20621520
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG]), n=24
Trial: 20621520
Drug: 24-hour intravenous
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour intravenous (IV) insulin infusion (ISI)
Trial: 12963171
Drug: Cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oral regimen of norethisterone acetate (1 mg on day 13‐22) and estradiol (days 1‐21; 2 mg, days 22‐28; 1 mg)
Trial: 6380212
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg/kg)
Trial: 26120981
Drug: Cytoflavin (10ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (10ml of the solution in one injection once a day in 200 ml of isotonic solution of sodium chloride intravenously in drops in the morning during 10 days)
Trial: 26120981
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (nonsteroid anti‐inflammatory drugs, myorelaxants, vitamins)
Trial: 23927582
Drug: Levofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (750 mg/day)
Trial: 11876707
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg/day)
Trial: 18469158
Drug: Once-weekly epoetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly epoetin alfa
Trial: 18469158
Drug: Control (twice-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (twice- or thrice-weekly epoetin alfa)
Trial: 12677616
Drug: Single-stimulation infraclavicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stimulation infraclavicular brachial plexus block (ICB) with 40 mL of ropivacaine 0.75%
Trial: 12677616
Drug: Triple-stimulation axillary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-stimulation axillary block (AxB) with 40 mL of ropivacaine 0.75%
Trial: 1873424
Drug: Oral tilidine-naloxone
RxNorm normalized name: naloxone / tilidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tilidine-naloxone
Trial: 30862999
Drug: Meal replacement
RxNorm normalized name: Diabetic meal replacement bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal replacement group (MR-G) with soy-yogurt-honey preparation
Trial: 21296862
Drug: rhG-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhG-CSF (10 µg/kg/day intravenous infusion once daily for 5 days)
Trial: 16392976
Drug: Voucher for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher for free methadone maintenance treatment (MMT)
Trial: 3440773
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate lozenges (23 mg)
Trial: 3440773
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo lozenges
Trial: 31429599
Drug: Resveratrol (RV)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (RV) 330 mg, 3 times a day for 3 days plus an additional 330 mg on the morning of the fourth day.
Trial: 23784266
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with quinidine 300 mg (n = 42)
Trial: 23784266
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with verapamil 240 mg (n = 34)
Trial: 23784266
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with digoxin 0.25 mg (n = 48)
Trial: 23784266
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with atorvastatin 80 mg (n = 32)
Trial: 21762407
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment in periodontitis patients
Trial: 11517272
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg orally)
Trial: 22006639
Drug: Scopolamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.4 mg, i.v.)
Trial: 9268187
Drug: Ardeparin sodium
RxNorm normalized name: ardeparin sodium
DrugBank: Ardeparin (DB00407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ardeparin sodium (10,000 anti-factor Xa U/ml with different preservatives)
Trial: 9268187
Drug: Ardeparin sodium
RxNorm normalized name: ardeparin sodium
DrugBank: Ardeparin (DB00407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ardeparin sodium (20,000 anti-factor Xa U/ml)
Trial: 9268187
Drug: Ardeparin sodium
RxNorm normalized name: ardeparin sodium
DrugBank: Ardeparin (DB00407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ardeparin sodium (all formulations)
Trial: 9268187
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment (control)
Trial: 3549029
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg X kg‐1)
Trial: 30458863
Drug: Combination gefitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination gefitinib (250 mg daily for 7 days) and methotrexate (50 mg/m2 single dose)
Trial: 30458863
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (50 mg/m2 single dose)
Trial: 18840369
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg once a day for 6 days with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6
Trial: 18840369
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg alone
Trial: 18840369
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg with azithromycin
Trial: 21125288
Drug: Intravenous abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous abciximab
Trial: 29082651
Drug: telbivudine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telbivudine (600 mg/d)
Trial: 29082651
Drug: entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entecavir (0.5 mg/d)
Trial: 25098924
Drug: 8-week proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week proton pump inhibitor (PPI) therapy with 20 mg of omeprazole for 56 days
Trial: 25098924
Drug: 1-week Helicobacter
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week Helicobacter pylori eradication therapy (40 mg of omeprazole, 1,500 mg of amoxicillin, and 800 mg of clarithromycin for 7 days) followed by 7-week rebamipide treatment (300 mg for 49 days)
Trial: 21067727
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (0.625 mg) with oral medroxyprogesterone acetate (5 mg) on 14 of the 28 days
Trial: 21067727
Drug: Natural E(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural E(2) gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days
Trial: 19185243
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 8% pH 6.0
Trial: 19185243
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 8%
Trial: 19185243
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 16% given 6 times
Trial: 11432535
Drug: Randomised dose-controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised dose-controlled trial (RDCT)
Trial: 8625167
Drug: IL-2 and
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 and PEG-IL-2 combination
Trial: 30920645
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SoC) chemotherapy
Trial: 28743240
Drug: Stereotactic radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic radiosurgery (SRS) with a single dose in the range of 15-24 Gy
Trial: 19412613
Drug: Standardized pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized pain therapy (Group 2)
Trial: 9550533
Drug: Intense nonpharmacological
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense nonpharmacological intervention including a low-fat, high-fiber diet and regular daily physical exercise
Trial: 3291938
Drug: Epostane (3-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epostane (3-beta hydroxy steroid dehydrogenase inhibitor)
Trial: 28912050
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) for 28 days
Trial: 24345055
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (n=9) - treated by the same protocol twice a day
Trial: 24345055
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care group (n=9) - received physical therapy according to daily custom protocol
Trial: 12616127
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Trial: 3901375
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline solution
Trial: 26969417
Drug: ABT-436 (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-436 (1,000 mg)
Trial: 22192967
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 500 μg
Trial: 22192967
Drug: Fluticasone-salmeterol combination,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone-salmeterol combination, 500/50 μg
Trial: 22192967
Drug: Salmeterol, 50
RxNorm normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 50 μg
Trial: 18411915
Drug: Drotaverine 80
RxNorm normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine 80 mg
Trial: 31904292
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone added to bupivacaine and epinephrine nerve blocks
Trial: 26385396
Drug: RVX-208 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX-208 200 mg
Trial: 11185671
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) dosage form of clomipramine
Trial: 11185671
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) dosage form of clomipramine
Trial: 9264751
Drug: Hygiene measures,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygiene measures, water sanitation, and oral rehydration therapy
Trial: 3898450
Drug: Intravenous 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5-fluorouracil (IV 5-FU)
Trial: 27555604
Drug: Oral silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral silymarin 420 mg daily in three divided doses for 6 weeks
Trial: 20194956
Drug: Daily isokinetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily isokinetic hamstring exercises starting at postoperative 3 weeks (group I)
Trial: 18343263
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d plus ASA 81 mg/d
Trial: 12701778
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of Depo‐Medrol (40 mg)
Trial: 12701778
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of sterile saline placebo (control)
Trial: 9372647
Drug: Prednisone 20
RxNorm normalized name: prednisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 20 mg/d in a prospectively tapered regimen (P)
Trial: 9372647
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with prednisone 20 mg/d and cyclosporin A 5 to 7 mg/kg/d (P-CsA)
Trial: 3005774
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus tamoxifen 20 mg/m2 Days 2-6 and premarin 0.625 mg Q 12-H X 3 on Day 7
Trial: 3005774
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without additional hormones
Trial: 3005774
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus tamoxifen and premarin in patients with inflammatory breast cancer
Trial: 6321686
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus tamoxifen and premarin
Trial: 28341722
Drug: BUPI (bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUPI (bupivacaine 0.46%, 0.46 mg/kg)
Trial: 28341722
Drug: BUPI-DEX (bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUPI-DEX (bupivacaine with dexmedetomidine 1 µg/kg)
Trial: 28341722
Drug: BUPI-BUPRE (bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUPI-BUPRE (bupivacaine with buprenorphine 2.5 µg/kg)
Trial: 25442243
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid 2000/125 mg
Trial: 14716792
Drug: Conventional densely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional densely woven polypropylene mesh (100‐110 g/m(2))
Trial: 14716792
Drug: Lightweight composite
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lightweight composite multifilament mesh (polypropylene 27‐30 g/m(2))
Trial: 9202916
Drug: Alizapride 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride 100 mg
Trial: 3281060
Drug: Alizapride 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride 200 mg
Trial: 18664303
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg)
Trial: 25366037
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 to 10 mg twice daily)
Trial: 19935091
Drug: c‐pharm early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c‐pharm early (sertraline at 150 mg/d)
Trial: 19935091
Drug: c‐pharm late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c‐pharm late (placebo initially, then sertraline at 150 mg/d)
Trial: 18035205
Drug: THC/CBD oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD oromucosal spray (27 mg/mL: 25 mg/mL)
Trial: 3913379
Drug: Prazosin 5
RxNorm normalized name: prazosin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 5 mg
Trial: 6932833
Drug: Prazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin therapy (4 weeks)
Trial: 22779383
Drug: Fluoridated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated milk (0.5 mgF per 189 ml carton)
Trial: 19921083
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg daily)
Trial: 7790946
Drug: Buprenorphine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (6 or 12 mg daily)
Trial: 2134443
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without steroid drug)
Trial: 340326
Drug: Cimetidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1200 mg per day for 6 weeks)
Trial: 381873
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg twice daily)
Trial: 17996996
Drug: Hib-MenCY-TT co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-MenCY-TT co-administered with DTPa-HBV-IPV and PCV7